Swedish Orphan Biovitrum AB (publ) (SWOBY) Discusses on NASP and Uncontrolled Gout Call

Core Insights - Sobi has received FDA acceptance for the filing package related to the NASP program for uncontrolled gout, indicating progress in their drug development efforts [1]. Group 1: Company Overview - Guido Oelkers serves as the CEO and President of Sobi, leading the discussion on the NASP program [1]. - The NASP program, formerly known as SEL-212, is a significant focus for Sobi, with key personnel involved in its development [4]. Group 2: Expert Involvement - Dr. Herbert Baraf, a Clinical Professor of Medicine and a senior clinical adviser, is participating in the discussion, bringing extensive experience from over 400 clinical trials, particularly in therapeutic gout [2][3]. - Dr. Rehan Azeem is the medical development lead for the NASP program, contributing to its research and development [4].